30 May 2017

Appointment of Jefferies and Stifel as joint corporate brokers

 

LONDON, 30 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces the appointment of Jefferies International Limited and Stifel Nicolaus Europe Limited to act as its joint corporate brokers with immediate effect.

 

For more information, please contact:

 

Arix Bioscience plc

Joe Anderson, CEO

+44 (0) 20 7290 1052

 

Jefferies International Limited

Simon Hardy, Christopher Binks

+44 (0) 20 7029 8000

 

Stifel Nicolaus Europe Limited

Jonathan Senior, Ben Maddison

+44 (0) 20 7710 7600

 

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

 


Back to previous page